These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11776326)

  • 1. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.
    Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C
    Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro.
    Hansen JB; Svensson B; Olsen R; Ezban M; Osterud B; Paulssen RH
    Thromb Haemost; 2000 Jun; 83(6):937-43. PubMed ID: 10896252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.
    Vignoli A; Marchetti M; Balducci D; Barbui T; Falanga A
    Haematologica; 2006 Feb; 91(2):207-14. PubMed ID: 16461305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium.
    Pérez-Ruiz A; Montes R; Carrasco P; Rocha E
    Clin Appl Thromb Hemost; 2002 Jan; 8(1):65-71. PubMed ID: 11991242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
    Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
    J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
    Brown JR; Kuter DJ
    Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
    Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
    Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative quantification of glycosaminoglycan-induced upregulation of TFPI-mRNA expression in vitro.
    Thyzel E; Kohli S; Siegling S; Prante C; Kleesiek K; Götting C
    Thromb Res; 2007; 119(6):785-91. PubMed ID: 16919311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.
    Lupu C; Poulsen E; Roquefeuil S; Westmuckett AD; Kakkar VV; Lupu F
    Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2251-62. PubMed ID: 10479670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bemiparin, dalteparin, and unfractionated heparin on platelet interaction with human subendothelium under flow conditions.
    González-Correa JA; Arrebola MM; Mérida F; Navas MD; López-Villodres JA; Samanes F; Cruz JP
    J Pharmacol Sci; 2008 May; 107(1):103-6. PubMed ID: 18490857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidylcholine decreases the synthesis of tissue factor pathway inhibitor in human umbilical vein endothelial cells.
    Sato N; Kokame K; Miyata T; Kato H
    Thromb Haemost; 1998 Jan; 79(1):217-21. PubMed ID: 9459350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
    Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
    Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.
    Marchetti M; Vignoli A; Russo L; Balducci D; Pagnoncelli M; Barbui T; Falanga A
    Thromb Res; 2008; 121(5):637-45. PubMed ID: 17692905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluid flow induces upregulation of synthesis and release of tissue factor pathway inhibitor in vitro.
    Westmuckett AD; Lupu C; Roquefeuil S; Krausz T; Kakkar VV; Lupu F
    Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2474-82. PubMed ID: 11073855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells.
    Nadir Y; Brenner B; Gingis-Velitski S; Levy-Adam F; Ilan N; Zcharia E; Nadir E; Vlodavsky I
    Thromb Haemost; 2008 Jan; 99(1):133-41. PubMed ID: 18217145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells.
    Xu Z; Maiti D; Kisiel W; Duh EJ
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2819-25. PubMed ID: 17023682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.
    Alban S
    Semin Thromb Hemost; 2001 Oct; 27(5):503-11. PubMed ID: 11668420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.